Memorandum


October 7, 2019

GOG-0252: A PHASE III CLINICAL TRIAL OF BEVACIZUMAB WITH IV VERSUS IP CHEMOTHERAPY IN OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CARCINOMA NCI-SUPPLIED AGENT(S): BEVACIZUMAB (NSC #704865, IND #113912)

All observations and tests can be performed when clinically indicated.


Observations and Tests (Protocol Section 7.0), requires post-treatment evaluation (including: History & Physical to include pelvic exam; Blood pressure; Toxicity Assessment; CA125; Radiologic Disease Assessment) every 3 months for 2 years, every 6 months for 3 years, then annually.  These (now annual) Observations and Tests can cease per protocol and be done only when clinically indicated.


The study remains open for survivorship follow up only (annual reporting).

Twitter
This message was sent from NRG-Broadcasts@NRGOncology.org to NRG-Broadcasts@NRGOncology.org
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address | Forward Email | Report Abuse